Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM) Clinical Trial

Official title:

Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus - a Feasible Clinical Trial Protocol

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05631561
• Other study ID #: MLWY-S220501
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 27, 2022
• Est. completion date: February 28, 2025

Study information

• Verified date: March 2024
• Source: Shanghai Golden Leaf MedTec Co. Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multicenter, single group feasibility clinical trial to evaluate the safety and efficacy of Endovascular denervation for the treatment of type 2 diabetes mellitus (T2DM) using the Endovascular denervation system (Generator and Catheter).

Description:

This is a prospective, multicenter, single group feasibility clinical trial. Patients with T2DM with poor glycemic control, glycated hemoglobin A1c (Hba1c) between 7.5% and 10.5% treatment with at least one to three oral antidiabetic drugs and/or insulin on the basis of metformin. All eligible patients will accept EDN treatment and were evaluated at 7, 30, 60, 90, 180, 365, 730 days post procedure. The primary safety endpoint is the number of composite major adverse events (MAE) * related to the study device and/or the denervation procedure during procedure and within 30 days after the procedure, the primary efficacy is Hba1c changes from baseline to 6 months post procedure.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: February 28, 2025
• Est. primary completion date: April 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Subject with age of >18 years old and<65 years old (both ends included)

2. Subjects understood the requirements and treatments of the trial, agreed to and were able to complete all follow-up assessments required for the trial, and signed informed consent before any special trial-related tests and treatments were performed

3. Diagnosed with T2DM for 1-15 years (according to WHO criteria)

4. Metformin (daily dose =1000mg) was combined with 1-3 Oads for more than 3 months and/or insulin (no dose limit). Specific Oads were: insulin secretagogues (sulfonylureas/glinides), thiazolidinediones (TZDS) and a-glucosidase inhibitors (see Note), and the combined Oads were at least half of the maximum approved dose in the package insert

5. The above OAD treatment is not effective for more than 3 months, and the glycosylated hemoglobin (HbA1c) level is between 7.5% and 10.5% (based on baseline examination)

6. Body mass index (BMI) between 18 and 40kg/m2 (both ends included)

Exclusion Criteria:

1. Type 1 diabetes or late-onset autoimmune diabetes in adults (LADA), or any secondary diabetes

2. Previous aortic disease (e.g., aortic aneurysm or dissection) or aortic surgery (including celiac artery denervation)

3. Baseline CTA showed aortic aneurysm or dissection, or anatomical abnormalities of the hepatic artery and its branches, or other abnormal vascular structure/status (e.g., severe tortuosity or stenosis of the artery, intraval thrombus, or unstable plaque) deemed by the investigator to be unsuitable for vascular ablation.

4. More than 2 self-reported or documented episodes of severe hypoglycemia in the past 6 months (defined as hypoglycemia with severe cognitive impairment requiring assistance from another person)

5. Have had more than one documented episode of hyperglycemia requiring hospitalization in the past 6 months, including diabetic ketoacidosis, hyperosmolar coma, etc

6. Severe diabetic complications, such as retinal, renal, vascular, neuropathy, and diabetic foot, were considered by the investigator to be ineligible for enrollment in this trial

7. Major cardiovascular and cerebrovascular events (MACCE) within the past 6 months, including cerebrovascular accident (CVA), transient cerebral ischemia (TIA), heart failure (NYHA class III-IV), acute myocardial infarction, or unstable angina requiring hospitalization (including previous coronary artery bypass grafting or coronary stent implantation); And uncontrolled or severe arrhythmias

8. Severe autonomic neuropathy (orthostatic hypotension, gastroparesis syndrome, etc.)

9. Untreated or uncontrolled high blood pressure (SBP=160mmHg or DBP=100mmHg), or low blood pressure (BP < 90/50 MMHG)

10. A history of renal insufficiency or failure with a baseline estimated glomerular filtration rate (eGFR) < 60mL/min/1.73m2 (see Note c of the Clinical Data collection Table in Table 5-2 for the eGFR formula)

11. Chronic active hepatitis, severe hepatobiliary disease (including cirrhosis), or hepatic insufficiency (alanine and/or aspartate aminotransferase > 3 times the upper limit of normal or serum total bilirubin > 2 times the upper limit of normal)

12. Acute and chronic pancreatitis during screening and baseline periods

13. Acute systemic infections during the screening and baseline periods

14. Bleeding tendency or coagulopathy (PT, APTT, or INR > 2 times the upper limit of normal; Platelet count < 80×109/L or = 700×109/L)

15. Active GI ulcer or GI bleeding within 3 months before baseline

16. Symptomatic cholelithiasis (including cholecystolithiasis, extrahepatic bile duct stones, and intrahepatic bile duct stones) but without effective treatment such as cholecystectomy, choledocholithotomy, internal drainage or external drainage

17. Hyperthyroidism, hypothyroidism, acromegaly, Cushing's syndrome and other endocrine and metabolic diseases

18. Autoimmune diseases

19. Diagnosed with a high risk of malignancy or cancer development/recurrence, or expected life expectancy < 12 months

20. History of major surgical procedures within the past 3 months

21. A condition or concomitant medical condition, such as hemoglobinopathy or hemolytic anemia, that could have prevented the primary end point from being assessed

22. Patients with mental illness who are unable to cooperate

23. Received treatment with a GLP-1 receptor agonist, DPP-4 inhibitor, or SGLT-2 inhibitor within 3 months before the screening period

24. Received systemic or intra-articular glucocorticoids (other than topical, inhaled, or eye drops) within 3 months before the screening period

25. Use of weight-loss medications such as orlistat or other possible treatments for weight loss (weight-loss tea/herbal medicine/acupuncture, etc.) within 3 months before the screening period

26. Prior or anticipated bariatric surgery such as subtotal gastrectomy/liposuction

27. Receipt of central sympathetic inhibitors or anticonvulsants within 3 months prior to or anticipated during the screening period

28. Long-term anticoagulation therapy is required but preoperative heparin bridging anticoagulation is not possible

29. Weight gain of more than 10% in the past 3 months

30. Allergy to or contraindication to contrast media, and inadequate pretreatment, as judged by the investigator

31. A known history of allergy to the study device (containing polytetrafluoroethylene or Nitinol) or to medications associated with the trial protocol

32. Were participating in other clinical studies or were participating in clinical studies within 3 months before enrollment

33. Expect to participate in a clinical trial of another drug or medical device within 24 months after baseline surgery

34. Pregnant or lactating women, or those planning to become pregnant within the next 2 years (all women of childbearing age must undergo a pregnancy test within 7 days before baseline surgery)

35. Drastic changes in diet and exercise habits are expected during the study (due to religious/work needs/weight loss, etc.)

36. Irregular day and night work (night shift workers)

37. History of alcohol/drug/substance abuse

38. Scheduled periodic blood product therapy or severe blood loss during the previous 3 months/study period

39. According to the investigator's judgment, there is any situation that affects the safety of the subjects or interferes with the evaluation of the test results

40. Subjects had aortic aneurysm or aortic dissection confirmed on angiography before EDN

41. The subject's vascular structure and conditions were considered by the investigator to be unsuitable for ablation (e.g., severe tortuosity or stenosis of the artery, abnormal vascular anatomy, intracavinal thrombus, or unstable plaque).

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus (T2DM)

Intervention

Device:
• Endovascular denervation System (Generator and Catheter )
All patients receive endovascular denervation (EDN) treatment

Locations

Country	Name	City	State
China	Zhongda Hospital, Southeast University	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Golden Leaf MedTec Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the composite of major adverse events (MAE)* related to the study device and/or the EDN procedure during procedure and within 30 days post procedure	The primary safety endpoint is the composite of major adverse events (MAE)* related to the study device and/or the EDN procedure during procedure and within 30 days post procedure	From index procedure to 30 days post procedure
Primary	The changes of Hba1c from baseline at 6 months post procedure	The primary efficacy is the changes of Hba1c from baseline at 6 months post procedure.	From baseline to 6 months post procedure
Secondary	The changes of Hba1c from baseline at 1, 3, 12 and 24 months post procedure	The changes of Hba1c from baseline at 1, 3, 12 and 24 months post procedure	From baseline to 1, 3, 12 and 24 months post procedure
Secondary	The changes of assessment of islet function and insulin resistance at 1, 3, 6, 12 and 24 months post procedure	The change of islet function and insulin resistance (HOMA-ß and HOMA-IR) from baseline at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	The changes of mean glucose, postprandial glucose increase, nocturnal glucose increase and time in target range (TIR) by 14-day ambulatory glucose monitoring (with non-invasive ambulatory glucose meter) at 1, 3, 6, 12 and 24 months post procedure	The changes of mean glucose, postprandial glucose increase, nocturnal glucose increase and time in target range (TIR) by 14-day ambulatory glucose monitoring (with non-invasive ambulatory glucose meter) at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	The changes of blood lipids at 1, 3, 6, 12 and 24 months post procedure	The changes of blood lipids (triglycerides, total cholesterol, HDL and LDL) from baseline to 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	The changes of liver function at 1, 3, 6, 12 and 24 months post procedure	The changes of blood liver function (ALT, AST, ALP and GGT) from baseline at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	The changes of renal function to 1, 3, 6, 12 and 24 months post procedure	The changes of blood renal function (urea nitrogen, blood creatinine and eGFR) from baseline at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	The changes of glucose in oral glucose tolerance test (OGTT) and insulin and C-peptide release tests from baseline to 6, 12, and 24 months post procedure	The changes of glucose in oral glucose tolerance test (OGTT) and insulin and C-peptide release tests from baseline to 6, 12, and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	Proportion of patients achieving target HbA1c (< 7.0% and =6.5%) at 1, 3, 6, 12 and 24 months post procedure	Proportion of patients achieving target HbA1c (< 7.0% and =6.5%) at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	Proportion of patients with HbA1c < 7% without hypoglycemia/severe hypoglycemia or weight gain at 1, 3, 6, 12 and 24 months post procedure	Proportion of patients with HbA1c < 7% without hypoglycemia/severe hypoglycemia or weight gain at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	Proportion of patients with the changes of in type/dose of antidiabetic drugs at 1, 3, 6, 12 and 24 months post procedure	Proportion of patients with the changes of in type/dose of antidiabetic drugs at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	Incidence of hypoglycemia and severe hypoglycemia (blood glucose level < 3.9 mmol/L) at 1, 3, 6, 12 and 24 months post procedure	Incidence of hypoglycemia and severe hypoglycemia (blood glucose level < 3.9 mmol/L) at 1, 3, 6, 12 and 24 months post procedure	From baseline to 1, 3, 6, 12 and 24 months post procedure
Secondary	The occurrence of new significant celiac or hepatic artery stenosis at 6 months post procedure (stenosis >50% as assessed by CTA and confirmed by DSA when CTA assessment shows abnormal)	The occurrence of new significant celiac or hepatic artery stenosis at 6 months post procedure (stenosis >50% as assessed by CTA and confirmed by DSA when CTA assessment shows abnormal)	From baseline to 7days, 1, 3, 6, 12 and 24 months post procedure
Secondary	The occurrence of device and/or procedure-related AEs and SAEs during procedure and 7 days, 1, 3, 6, 12 and 24 months post procedure	The occurrence of device and/or procedure-related AEs and SAEs during procedure and 7 days, 1, 3, 6, 12 and 24 months post procedure	From baseline to 12 and 24 months post procedure
Secondary	Incidence of cardiovascular and cerebrovascular complications (3MACE, defined as cardiovascular death, myocardial infarction and ischemic stroke) at 12 and 24 months post procedure	Incidence of cardiovascular and cerebrovascular complications (3MACE, defined as cardiovascular death, myocardial infarction and ischemic stroke) at 12 and 24 months post procedure	From baseline to 12 and 24 months post procedure
Secondary	Quality of life assessment (EQ-5D-5L) at pre-procedure and 6 months post procedure	Quality of life assessment (EQ-5D-5L) at pre-procedure and 6 months post procedure	Before procedure to 6 months post procedure